Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells

Abstract

AbstractPurposeThis research aimed to find potential HER2 mutations that would have an impact on breast cancer and investigate the underlying mechanism.Experimental designThis study first investigated 238 pairs of breast cancer and para‐cancerous tissue samples from patients on the targeted next‐generation sequencing (tNGS) platform. CCK‐8 and clone formation assay were used to investigate whether the mutation exerts proliferative effects on breast cancer cells. In addition, mass spectrometry‐based comparative proteomic and phosphoproteomic analyses of the mutation types and wild types of MCF‐7 cell lines were carried out.ResultsAmong the identified mutations, a new mutation HER2 L796P promoted the proliferation of breast cancer cells and had resistance to lapatinib using CCK‐8 cell proliferation assay and clone formation assay. The bioinformatic analysis showed that RAS family proteins and ERK phosphorylated proteins significantly increased in the L796P mutant cells. The Gene Ontology (GO) analysis revealed that L796P mutation affected the function of breast cancer at the level of upstream genes in the MAPK and PI3K‐AKT‐TOR pathways.Conclusions and clinical relevanceThis study demonstrated that a rare mutation HER2 L796P could be a potential therapeutic target for the clinical management of breast cancer.